Big Tech and pharmaceutical companies are accelerating the implementation of artificial intelligence in the healthcare ...

The table below is a review of notable updates that occurred in January 2025 for investigational products in development.

German Merck said it plans to combine its scientific ... They will also focus on diabetes, thyroid disorders and cardiovascular diseases, as well as oncology including metastatic colorectal ...

Exelixis, Inc. EXEL reported better-than-expected fourth-quarter results. EXEL recorded earnings of 55 cents per share, which beat the Zacks Consensus Estimate of 51 cents. The company registered ...

Presentation Unidentified Speaker Thank you. Thank you, Julianne. Good afternoon, everyone, and welcome to our 4th-quarter ...

Merck booked just under $600 million last year in alliance revenues from the pair, but its attention is now moving to new therapies including sotatercept, a TGF-beta-targeting PAH drug Merck ...

Portfolio Receipts of $742 million in Q4 2024 and $2,801 million for FY 2024Royalty Receipts growth of 12% in Q4 2024 and 13% for FY 2024 Net ...

Many people have experience with thyroid disorders, including celebrities. Gigi Hadid, Wendy Williams, and Oprah Winfrey have opened up about their thyroid health. The thyroid is a butterfly ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Eli Lilly and Company's impressive Q4 earnings driven by tirzepatide's success, diverse portfolio, and promising pipeline.

Equities researchers at William Blair decreased their Q1 2025 earnings per share estimates for shares of Viking Therapeutics in a research note issued to investors on Wednesday, February 5th. William ...